Bide Pharmaceutical

Shanghai Bide Pharmaceutical Technology Joint-stock Co., Ltd., established in 2007, is a high-tech enterprise adhering to the basic value of serving people's life and health, focusing on the front end of the new drug R&D industry chain, relying on the core business of R&D design, production and sales of drug building blocks. It is able to provide new drug R&D institutions with drug building blocks and scientific reagents that are novel in structure and diverse in function, and is recognized as a specialized and innovative "little giant" enterprise.
The company's end customers are mainly innovative drug enterprises, research institutes, CRO institutions and other new drug R&D institutions. Its products mainly serve key links in new drug R&D, such as drug target discovery, hit compound synthesis and screening, lead compound discovery, synthesis and optimization, and drug candidate compound discovery. Guided by theories such as drug structure-activity relationships, structure-property relationships, and retrosynthetic analysis of drug compounds, the company has closely tracked the dynamics of new molecular entities (NMEs) for many years, forming a core technology system represented by drug building block R&D design, customized synthesis, molecular structure confirmation, purity testing and purification. It has built a product library of drug building blocks with comprehensive categories and large scale, capable of meeting customers' demands for high technology, multiple categories, micro doses, and high frequency in terms of drug building blocks.
The company is committed to becoming a frontier enterprise in the global drug building block field and actively carries out global layout. It has established regional centers in the United States, Europe, India and other global hotspots for new drug R&D, achieving close tracking of frontier pharmaceutical R&D directions, timely development of drug building blocks with unique structures and diverse functions, and rapid response to customers' diverse needs for drug building blocks and scientific reagents, thereby helping global new drug R&D institutions accelerate new drug R&D processes or reduce R&D costs.